WO2019161534A1 - Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble - Google Patents

Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble Download PDF

Info

Publication number
WO2019161534A1
WO2019161534A1 PCT/CN2018/076982 CN2018076982W WO2019161534A1 WO 2019161534 A1 WO2019161534 A1 WO 2019161534A1 CN 2018076982 W CN2018076982 W CN 2018076982W WO 2019161534 A1 WO2019161534 A1 WO 2019161534A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
base
salt
optionally
Prior art date
Application number
PCT/CN2018/076982
Other languages
English (en)
Inventor
Fenger ZHOU
Yuguang Wang
Takashi Nakai
Vishnu Karnati
Wayne C. Schairer
William KISSEL
Song Xue
Ahmad Hashash
Original Assignee
Ironwood Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals, Inc. filed Critical Ironwood Pharmaceuticals, Inc.
Priority to PCT/CN2018/076982 priority Critical patent/WO2019161534A1/fr
Priority to TW108101044A priority patent/TWI821237B/zh
Priority to US16/961,109 priority patent/US11274096B2/en
Priority to JOP/2020/0165A priority patent/JOP20200165A1/ar
Priority to MA051565A priority patent/MA51565A/fr
Priority to KR1020207022640A priority patent/KR20200106920A/ko
Priority to CN202410363182.2A priority patent/CN118184645A/zh
Priority to PCT/US2019/013060 priority patent/WO2019140095A1/fr
Priority to SG11202006311SA priority patent/SG11202006311SA/en
Priority to EP23187776.2A priority patent/EP4249469A3/fr
Priority to JP2020538535A priority patent/JP7357621B2/ja
Priority to TW112138274A priority patent/TW202402741A/zh
Priority to EP19703440.8A priority patent/EP3737679B1/fr
Priority to ES19703440T priority patent/ES2963447T3/es
Priority to MX2020007364A priority patent/MX2020007364A/es
Priority to CN201980017700.2A priority patent/CN111902410B/zh
Priority to CN202410363184.1A priority patent/CN118221665A/zh
Priority to AU2019206560A priority patent/AU2019206560B2/en
Priority to CA3087943A priority patent/CA3087943A1/fr
Priority to EA202091664A priority patent/EA202091664A1/ru
Priority to BR112020013985-8A priority patent/BR112020013985A2/pt
Publication of WO2019161534A1 publication Critical patent/WO2019161534A1/fr
Priority to IL275748A priority patent/IL275748A/en
Priority to CL2020001814A priority patent/CL2020001814A1/es
Priority to MX2023000045A priority patent/MX2023000045A/es
Priority to MX2023000044A priority patent/MX2023000044A/es
Priority to US17/497,352 priority patent/US11708361B2/en
Priority to CL2022000904A priority patent/CL2022000904A1/es
Priority to CL2022000907A priority patent/CL2022000907A1/es
Priority to US18/140,966 priority patent/US12030874B2/en
Priority to JP2023162922A priority patent/JP2023182647A/ja
Priority to AU2023270260A priority patent/AU2023270260A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present disclosure relates to novel processes and intermediates for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC) . These processes produce stable 3- (2-pyrimidinyl) pyrazoles of Formula I in high purity and yields. These processes have the additional advantage of involving facile reaction conditions that are amenable to scale up for large scale manufacturing.
  • sGC soluble guanylate cyclase
  • sGC is the primary receptor for NO in vivo.
  • sGC can be activated via both NO-dependent and NO-independent mechanisms.
  • sGC converts guanosine-5'-triphosphate (GTP) into the secondary messenger cGMP.
  • GTP guanosine-5'-triphosphate
  • the increased level of cGMP in turn, modulates the activity of downstream effectors including protein kinases, phosphodiesterases (PDEs) and ion channels.
  • NO is synthesized from arginine and oxygen by various nitric oxide synthase (NOS) enzymes and by sequential reduction of inorganic nitrate.
  • NOS nitric oxide synthase
  • sGC stimulators are NO-independent, heme-dependent modulators of the sGC enzyme, and display strong synergistic enzyme activation with NO. These are clearly differentiated from NO-independent, heme-independent sGC activators.
  • compounds of Formula I and their pharmaceutically acceptable salts are sGC stimulators useful for treating diseases or disorders that benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP) .
  • compounds of Formula I are useful intermediates in the preparation of said sGC stimulators.
  • R 1 is phenyl, or a 5 to 6-membered heteroaryl ring; optionally substituted with up to three instances independently selected from the group consisting of halogen or methyl; wherein said 5 or 6-membered heteroaryl ring contains up to 3 ring atoms selected from the group consisting of N, S or O;
  • R 2 is phenyl or a 6-membered heteroaryl, optionally substituted with up to three instances of R 5 ; wherein said 6-membered heteroaryl ring contains up to 2 nitrogen ring atoms;
  • R 4 is chloro, -OMe or -NR 6 R 7 ;
  • each R 5 is independently methyl, methoxy or halogen
  • R 6 is hydrogen or C 1-4 alkyl substituted with 0 to 3 instances of R 8 ;
  • R 7 is hydrogen or C 1-4 alkyl substituted with 0 to 3 instances of R 8 ;
  • each R 8 is independently –OH, C 1-3 haloalkyl, halogen or –C (O) NH 2 .
  • a compound of Formula I is a compound of Formula II.
  • a compound of Formula I is a compound of Formula III.
  • a compound of Formula I is a compound of Formula IV.
  • a compound of Formula I is a compound of Formula V.
  • a compound of Formula VI is a compound of Formula VI.
  • a compound of Formula I is a compound of Formula VII.
  • a compound of Formula I is Compound IA.
  • a compound of Formula I is a compound of Formula IA.
  • a compound of Formula I is a compound of Formula IC.
  • a compound of Formula I is a compound of Formula ID.
  • the present invention provides a process for preparing a compound of formula (4) :
  • R 1 is phenyl, or a 5 to 6-membered heteroaryl ring; optionally substituted with up to three instances independently selected from the group consisting of halogen or methyl; wherein said 5 or 6-membered heteroaryl ring contains up to 3 ring atoms selected from the group consisting of N, S or O.
  • the present invention provides a process for preparing a compound of Formula II:
  • R 1 is phenyl, or a 5 to 6-membered heteroaryl ring; optionally substituted with up to three instances independently selected from the group consisting of halogen or methyl; wherein said 5 or 6-membered heteroaryl ring contains up to 3 ring atoms selected from the group consisting of N, S or O; and
  • R 2 is phenyl or a 6-membered heteroaryl, optionally substituted with up to three instances of R 5 ; wherein said 6-membered heteroaryl ring contains up to 2 nitrogen ring atoms; and each R 5 is independently methyl, methoxy or halogen.
  • the present invention provides a process for preparing a compound of formula III:
  • the present invention provides a process of preparing a compound of Formula IV:
  • R 1 is phenyl, or a 5 to 6-membered heteroaryl ring; optionally substituted with up to three instances independently selected from the group consisting of halogen or methyl; wherein said 5 or 6-membered heteroaryl ring contains up to 3 ring atoms selected from the group consisting of N, S or O;
  • R 2 is phenyl or a 6-membered heteroaryl, optionally substituted with up to three instances of R 5 ; wherein said 6-membered heteroaryl ring contains up to 2 nitrogen ring atoms,
  • each R 5 is independently methyl, methoxy or halogen
  • R 6 is hydrogen or C 1-4 alkyl substituted with 0 to 3 instances of R 8 ;
  • R 7 is hydrogen or C 1-4 alkyl substituted with 0 to 3 instances of R 8 ;
  • each R 8 is independently –OH, C 1-3 haloalkyl, halogen or –C (O) NH 2 .
  • the compound of formula (2) is prepared by a process comprising the steps of:
  • the compound of formula (1) is prepared by reacting a carboxylic acid of formula (8) :
  • the process comprises contacting the reaction product of the amide of formula (1) and the pyrimidine compound of formula (2) with a solution comprising N, O-dimethylhydroxylamine or a salt thereof and an acid to form the compound of formula (4) .
  • the acid is an aqueous acid. More specifically, the acid is hydrochloric acid. In another embodiment, the acid is a non-aqueous acid. More specifically, the acid is glacial acetic acid.
  • R 1 is a 5-membered heteroaryl ring. In other embodiments, R 1 is a 5-membered heteroaryl ring.
  • R 2 is phenyl optionally substituted with up to two instances of R 5 .
  • R 2 is phenyl optionally substituted with one instance of R 5 .
  • R 2 is a 6-membered heteroaryl, optionally substituted with up to two instances of R 5 ; and wherein said 6-membered heteroaryl ring contains up to 2 nitrogen ring atoms.
  • each R 5 is independently methyl or halogen. In some embodiments, each R 5 is independently halogen. In other embodiments, each R 5 is fluoro.
  • R 6 is hydrogen or C 1-2 alkyl substituted with 0 to 3 instances of R 8 . In some embodiment, R 6 is hydrogen.
  • R 7 is hydrogen or C 1-2 alkyl substituted with 0 to 3 instances of R 8 . In some embodiments, R 7 is C 1-2 alkyl substituted with 3 instances of R 8 .
  • each R 8 is independently –OH, trifluoromethyl, or –C (O) NH 2 .
  • R 1 is an unsubstituted 5-membered heteroaryl ring containing up to 2 ring heteroatoms selected from the group consisting of N and O;
  • R 2 is phenyl, optionally substituted with one or two instances of R 5 ;
  • each R 5 is fluoro
  • R 6 is hydrogen
  • R 7 is C 1-2 alkyl substituted with 3 instances of R 8 ;
  • each R 8 is independently –OH, trifluoromethyl, or –C (O) NH 2 .
  • the present invention provides a process of preparing a compound of formula (4’ ) :
  • the present invention provides a process of preparing a compound of Formula V:
  • the present invention provides a process of preparing a compound of Formula VI:
  • the present invention provides a process of preparing a compound of formula VII:
  • R 6 is hydrogen or C 1-4 alkyl substituted with 0 to 3 instances of R 8 ;
  • R 7 is hydrogen or C 1-4 alkyl substituted with 0 to 3 instances of R 8 ;
  • each R 8 is independently –OH, C 1-3 haloalkyl, halogen or –C (O) NH 2 .
  • the compound of formula (2) is prepared by a process comprising the steps of:
  • the compound of formula (1’ ) is prepared by reacting a carboxylic acid of formula (8’ ) :
  • R 6 is hydrogen or C 1-2 alkyl substituted with 0 to 3 instances of R 8 . In some embodiments, R 6 is hydrogen.
  • R 7 is hydrogen or C 1-2 alkyl substituted with 0 to 3 instances of R 8 . In some embodiments, R 7 is C 1-2 alkyl substituted with 3 instances of R 8 .
  • R 8 is independently –OH, trifluoromethyl, or –C (O) NH 2 .
  • R 6 is hydrogen; R 7 is C 1-2 alkyl substituted with 3 instances of R 8 and each R 8 is independently –OH, trifluoromethyl, or –C (O) NH 2 .
  • the present invention provides a process of preparing a compound of Formula IA:
  • the process of the 14 th specific embodiment further comprises recrystallization of the compound of Formula IA.
  • the process further comprises recrystallization of the compound of Formula IA in a mixture of methanol and water.
  • the recrystallization comprises the steps of: A’ ) dissolving the compound of Formula IA in methanol at a temperature between 30 °C and 65 °C to obtain a methanol solution of the compound of Formula IA; B’ ) filtering the methanol solution of the compound of Formula IA from step A’ ) to form a filtered methanol solution of the compound of Formula IA; C’ ) adding water to the filtered methanol solution of the compound of Formula IA at a temperature between 50 °C and 60 °C to yield a slurry; D’ ) cooling the slurry of step C’ ) to yield a recrystallized compound of Formula IA; and E’ ) filtering and drying the recrystallized compound of Formula IA.
  • the present invention provides a process of preparing a compound of Formula IB:
  • the present invention provides a process of preparing a compound of Formula IC:
  • the present invention provides a process of preparing a compound of Formula ID:
  • the present invention provides a process of preparing a compound of Formula IC:
  • the present invention provides a process of preparing a compound of Formula ID:
  • the process of the 19 th specific embodiment further comprises a step of recrystallization of the compound of Formula ID to yield crystalline Form B of the compound of Formula ID.
  • the recrystallization comprises the steps of: A” ) dissolving the compound of Formula ID in acetonitrile and water at a temperature between 70 °C and 75 °C to form a solution of the compound; B” ) filtering the solution of step A” ) to form a filtered solution of the compound; C” ) heating the filtered solution at a temperature between 65 °C and 75 °C and adding water to yield a slurry; D” ) cooling the slurry of step C” ) to a temperature between 0 to 5 °C to yield crystalline Form B of the compound of Formula ID; and E” ) filtering, washing with a mixture of acetonitrile and water, and drying the crystalline Form B of the compound of Formula ID.
  • the compound of formula (2) is prepared by a process comprising the steps of:
  • the compound of formula (1’ ) is prepared by reacting a carboxylic acid of formula (8’ ) :
  • the process comprises contacting the reaction product of the reaction between the amide of formula (1’ ) and the pyrimidine compound of formula (2) with a solution comprising N, O-dimethylhydroxylamine or a salt thereof and an acid to form the compound of formula (4’ ) .
  • the acid is an aqueous acid. More specifically, the acid is hydrochloric acid. In another embodiment, the acid is a non-aqueous acid. More specifically, the acid is glacial acetic acid.
  • N, O-dimethylhydroxylamine or a salt (e.g., hydrochloride salt) thereof is added in step ii) .
  • the intermediate of formula (3) or (3’ ) formed in step i) is isolated and then reacted withN,O-dimethylhydroxylamine or a salt (e.g., hydrochloride salt) thereof at a pH >5 to form the compound of formula (4) or (4’ ) respectively.
  • a salt e.g., hydrochloride salt
  • the base in step i) is n-butyllithium.
  • the aprotic solvent in step i) is THF, hexane or a mixture of THF and hexane.
  • 0.5 or 0.6 equivalents of N, O-dimethylhydroxylamine hydrochloride for every one equivalent of the pyrimidine compound formula (2) is used in the reaction of step ii) .
  • a base is present in the reaction of step iii) .
  • the base is potassium carbonate.
  • de-methylation in step iv) is carried out using an aqueous acid and the aqueous acid is HCl.
  • a base is present in the reaction of step vi) .
  • the base is Hunig’s base.
  • a base is not present in the reaction of step vi) .
  • the methoxide salt in step a) is MeONa, MeOLi, MeOK or MeOCs.
  • the base is MeONa.
  • the aprotic organic solvent in step b) is an ether.
  • the ether is methyl-tert-butyl ether.
  • the base in step c) is triethylamine, Hunig’s base, Et 2 NH, iPr 2 NH, piperidine, pyrrolidine, K 2 CO 3 , Na 2 CO 3 , Cs 2 CO 3 , or K 3 PO 4 .
  • the base is triethylamine.
  • a Cu (I) catalyst and a Pd catalyst are present in the reaction of step c) .
  • the Cu (I) catalyst is CuCl, CuBr, CuI or CuOTf.
  • the Cu (I) catalyst is CuI.
  • the Pd catalyst is PdCl 2 (PPh 3 ) 2 .
  • de-silylation in step c) is carried out using a fluoride reactant.
  • the fluoride reactant is KF.
  • oxalyl chloride is reacted with the compound of formula (8) or (8’ ) , followed by N,O-dimethylhydroxylamine hydrochloride in the presence of a base.
  • the base is K 2 CO 3 .
  • Also provided by the present invention are compounds prepared by the processes of the present invention.
  • the present invention is directed to a compound of formula (3) , (4) , (3’ ) , (4’ ) , (14) , (18) , (15) , (19) , (20) or (21) .
  • R 1 is a 5-membered heteroaryl ring.
  • R 1 is an unsubstituted 5-membered heteroaryl ring containing up to 2 ring heteroatoms selected from the group consisting of N and O.
  • the present invention provides crystalline Form A of the compound of Formula IA.
  • Form A is characterized by XRPD pattern substantially similar to that shown in FIG. 1.
  • Form A has the XRPD pattern as shown in FIG. 1.
  • Form A has at least one, two, three, four, five, six, seven or eight major peaks in an x-ray powder diffraction (XRPD) pattern selected from 4.2, 9.1, 9.8, 17.2, 17.7, 18.2, 27.5, and 36.0 degree 2 ⁇ angles.
  • XRPD x-ray powder diffraction
  • Form A has an endothermic onset (i.e., melting point) at a temperature between 155 °C and 170 °C, between 160 °C and 165 °C, between 162 °C and 164 °C, or between 162.5 °C and 163.5 °C in a differential scanning calorimetry (DSC) profile.
  • Form A has an endothermic onset at 163.1 °C.
  • a composition of compound of formula IA has at least 70%, 80%, 90%, 95%, 98%, 99%, 99.5%, or 99.9%by weight of the compound is the crystalline Form A of the compound.
  • FIG. 1 shows an XRPD pattern of crystalline Form A of the compound of Formula IA.
  • FIG. 2 shows a DSC profile of crystalline Form A of the compound of Formula IA.
  • FIG. 3A shows an XRPD pattern of crystalline Form B of the compound of Formula ID in the 2 ⁇ angle range of 5 to 45 degrees.
  • FIG. 3B shows an XRPD pattern of crystalline Form B of the compound of Formula ID before and after storage for 14 months.
  • FIG. 3C shows an XRPD pattern of crystalline Form B of the Compound of Formula ID in the 2 ⁇ angle range of 3 to 40 degrees.
  • ring atom refers to an atom such as C, N, O or S that is part of a ring
  • rings include, for example, a cycloaliphatic ring (e.g. a cycloalkyl ring) , a heterocyclic ring, an aryl ring (e.g., a phenyl ring) or a heteroaryl ring) .
  • a “substitutable ring atom” is a ring carbon or nitrogen atom bonded to at least one hydrogen atom.
  • the hydrogen can be optionally replaced with a suitable substituent group.
  • “Substitutable ring atom” does not include ring carbon or nitrogen atoms wherein the structure depicts that they are already attached to one or more moieties or substituents other than hydrogen and no hydrogens are available for substitution. When a certain ring is optionally substituted, it will be understood that it may be substituted at one or some or all of its substitutable ring atoms, depending on the number of substituents allowed.
  • substituted refers to the replacement of one or more hydrogen radicals of a given structure with another specified radical substituent, different from hydrogen (some non-limiting examples would be a hydroxy, a phenyl, or an alkyl radical) . If a structure or moiety is “optionally substituted” it may be substituted or unsubstituted.
  • the substituent or substitutents at each position may be “independently selected” to be equal or the same at each position and for each instance, unless otherwise specified.
  • a phenyl is substituted with two instances of R 100 , and each R 100 is independently selected from halogen and methyl, that means that each instance of R 100 is separately selected from halogen or methyl; for instance, one R 100 may be fluoro and one may be methyl, or both may be chloro, etc.
  • a substitutable atom is bonded to more than one hydrogen (e.g., CH 3 or NH 2 )
  • the substitutents may be “independently selected” to be equal or the same at each position and for each instance, unless otherwise specified.
  • a methyl e.g., CH 3
  • each R 100 is independently selected from halogen and methyl, that means that each instance of R 100 is separately selected from halogen or methyl; for instance, one R 100 may be fluoro and one may be methyl (e.g., CHF (CH 3 ) , or both may be chloro (e.g., CHCl 2 ) , etc.
  • substituents and combinations envisioned by this disclosure are only those that result in the formation of stable or chemically feasible compounds. Such choices and combinations will be apparent to those of ordinary skill in the art and may be determined without undue experimentation.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in some embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a chemically feasible compound is a compound that can be prepared by a person skilled in the art based on the disclosures herein, supplemented, if necessary, by relevant knowledge of the art.
  • up to refers to zero or any integer number that is equal or less than the number following the phrase.
  • up to 3 means any one of 0, 1, 2, or 3.
  • a specified number range of atoms or of substituents includes any integer therein.
  • a group having from 1-4 atoms could have 1, 2, 3 or 4 atoms.
  • any variable occurs more than one time at any position, its definition on each occurrence is independent from every other occurrence.
  • a group is substituted with 0 instances of a certain variable, this means the group is unsubstituted.
  • structures depicted herein are also meant to include all stereoisomeric (e.g., enantiomeric, diastereomeric, atropoisomeric and cis-trans isomeric) forms of the structure; for example, the Rand S configurations for each asymmetric center, Ra and Sa configurations for each asymmetric axis, (Z) and (E) double bond configurations, and cis and trans isomers. Therefore, single stereochemical isomers as well as racemates, and mixtures of enantiomers, diastereomers, and cis-trans isomers of the present compounds are within the scope of the present disclosure. Unless otherwise stated, all tautomeric forms of the compounds of the present disclosure are also within the scope of the invention.
  • the present disclosure may include replacement of hydrogen with deuterium (i.e., 2 H) , which may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • deuterium labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples herein below, by substituting a deuterated reagent for a non-deuterated reagent.
  • aliphatic as in, for example, “aliphatic group” or “aliphatic chain” , means an unbranched or branched hydrocarbon (formed by only carbon and hydrogen) chain that is completely saturated or that contains one or more units of unsaturation.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, alkyl, alkenyl, or alkynyl groups.
  • Specific examples of aliphatic groups include, but are not limited to: methyl, ethyl, propyl, butyl, isopropyl, isobutyl, vinyl, sec-butyl, tert-butyl, butenyl, propargyl, acetylene and the like.
  • An aliphatic group will be represented by the term “C x-y aliphatic” ; wherein x and y are the minimum and the maximum number of carbon atoms forming the aliphatic chain.
  • An aliphatic group will be represented by the term “C x aliphatic” to indicate that it is formed by x number of carbon atoms.
  • alkyl refers to a saturated unbranched (e.g., linear) or branched monovalent hydrocarbon radical.
  • a C x alkyl is an alkyl chain containing x carbon atoms, wherein x is an integer different from 0.
  • a “C x-y alkyl” wherein x and y are two different integers, both different from 0, is an alkyl chain containing between x and y number of carbon atoms, inclusive.
  • a C 1-6 alkyl is an alkyl as defined above containing any number of between 1 and 6 carbon atoms.
  • alkyl groups include, but are not limited to, methyl (i.e., C 1 alkyl) , ethyl (i.e., C 2 alkyl) , n-propyl (a C 3 alkyl) , isopropyl (adifferent C 3 alkyl) , n-butyl, isobutyl, s-butyl, t-butyl, pentyl, hexyl, heptyl, octyl and the like.
  • alkenyl refers to an unbranched (e.g., linear) or branched monovalent hydrocarbon radical with at least one site of unsaturation that is a carbon-carbon, sp 2 double bond, wherein the alkenyl radical includes radicals having “cis” and “trans” orientations, or using an alternative nomenclature, “E” and “Z” orientations.
  • alkenyls include, but are not limited to, vinyl, allyl and the like.
  • a C x alkenyl is an alkenyl chain containing x carbon atoms, wherein x is an integer different from 0 or 1.
  • an alkenyl group will be represented by the term “C x-y alkenyl” ; wherein x and y are the minimum and the maximum number of carbon atoms forming the alkenyl chain.
  • alkynyl refers to an unbranched (e.g., linear) or branched monovalent hydrocarbon radical with at least one site of unsaturation that is a carbon-carbon sp triple bond. Examples include, but are not limited to, ethynyl, propynyl, and the like.
  • a C x alkynyl is an alkynyl chain containing x carbon atoms, wherein x is an integer different from 0 or 1.
  • an alkynyl group will be represented by the term “C x-y alkynyl” ; wherein x and y are the minimum and the maximum number of carbon atoms forming the alkynyl chain.
  • cycloaliphatic refers to a ring system formed only by carbon and hydrogen atoms that is completely saturated or that contains one or more units of unsaturation but which is not aromatic.
  • a C x cycloaliphatic is a cycloaliphatic ring containing x carbon atoms, wherein x is an integer different from 0.
  • a cycloaliphatic ring will be represented by the term “C x-y cycloaliphatic” ; wherein x and y are the minimum and the maximum number of carbon atoms forming the cycloaliphatic ring.
  • Suitable cycloaliphatic groups include, but are not limited to, cycloalkyl, cycloalkenyl, and cycloalkynyl.
  • aliphatic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, norbornyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
  • cycloaliphatic also includes polycyclic ring systems (e.g., bicyclic, tricyclic or tetracyclic) ) .
  • the polycyclic ring system may be a bridged, a fused, or a spiro system.
  • “Bridged” ring systems comprise two rings which share two non-adjoining ring atoms.
  • “Fused” ring systems comprise two rings which share two adjoining ring atoms.
  • “Spiro” ring systems comprise two rings which share one adjoining ring atom.
  • cycloalkyl refers to a ring system formed only by carbon and hydrogen atoms which is completely saturated.
  • Suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cycloheptenyl, norbornyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
  • a cycloalkyl ring will be represented by the term “C x-y cycloalkyl” ; wherein x and y are the minimum and the maximum number of carbon atoms forming the cycloalkyl ring.
  • the term “cycloalkyl” also includes polycyclic ring systems (e.g., bicyclic, tricyclic or tetracyclic) .
  • the polycyclic ring system may be a bridged, a fused, or a spiro system.
  • aryl refers to a ring system formed only by carbon atoms that is aromatic.
  • the term also includes polycyclic ring systems (e.g., bicyclic, tricyclic, tetracyclic, etc. ) .
  • Examples of aryl rings include, but are not limited to, phenyl, naphthyl, indenyl, fluorenyl, and anthracenyl.
  • heteroatom refers to one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon, including any oxidized form of nitrogen, sulfur, phosphorus, or silicon, and including the quaternized form of any basic nitrogen.
  • a ring that includes atoms other than just carbon is termed a “heterocyclyl” (or “heterocycle” or “heterocyclic” ) , as in “heterocyclyl group” or “heterocyclyl ring” or a heteroaryl” (or “heteroaromatic” ) , as in “heteroaryl group” or “heteroaryl ring” .
  • Heterocyclyl and heteroaryl rings include at least one ring atom other than carbon to form the ring.
  • the non-carbon ring atom can be any suitable atom, but often is selected from nitrogen, oxygen, or sulfur.
  • Heterocyclyl rings are completely saturated (e.g., piperidinyl) or contain one or more units of unsaturation but is not aromatic (e.g., 1, 2, 3, 4-tetrahydropyridinyl or 1, 2-dihydropyridinyl) .
  • Heteroaryl rings are aromatic (e.g., pyridinyl) .
  • the terms heterocyclyl and heteroaryl also include polycyclic ring systems (e.g., bicyclic, tricyclic or tetracyclic) .
  • the polycyclic ring system may be a bridged, a fused, or a spiro system.
  • Heterocyclic rings include, but are not limited to, the following monocycles: 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4- thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolid
  • Heteroaryl rings include, but are not limited to the following monocycles: 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl) , 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl) , triazolyl (e.g., 2-triazolyl and 5-triazolyl) ,
  • alkoxy refers to an alkyl group, as previously defined, attached to the molecule through an oxygen atom.
  • An alkoxy group may be represented by -O- (C x-y alkyl) , wherein x and y represent the minimum and maximum number of carbons of the alkyl chain.
  • haloalkyl haloalkenyl
  • haloaliphatic haloalkoxy
  • haloalkoxy mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more halogen atoms.
  • a C 1-3 haloalkyl could be, for example -CFHCH 2 CHF 2 and a C 1-2 haloalkoxy could be, for example -OC (Br) HCHF 2 .
  • This term includes perhalogenated alkyl groups, such as –CCl 3 and –CF 2 CClF 2 .
  • fluoroalkyl means alkyl substituted with one or more fluorine atoms. This term includes perfluorinated alkyl groups, such as –CF 3 and –CF 2 CF 3 .
  • cyano refers to –CN or -C ⁇ N.
  • amino refers to —NH 2 .
  • hydroxyl or “hydroxy” refers to -OH.
  • an “oxo’ group is listed as a possible substituent on a ring or another moiety or group (e.g. an alkyl chain) it will be understood that the bond between the oxygen in said oxo group and the ring, or moiety or group it is attached to will be a double bond.
  • the compounds of the invention are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound’s identity.
  • amide coupling agent or “amide coupling reagent” means a compound that reacts with the hydroxyl moiety of a carboxy moiety thereby rendering it susceptible to nucleophilic attack.
  • exemplary amide coupling agents include DIC (diisopropylcarbodiimide) , EDCI (1-ethyl-3- (3-dimethylaminopropyl) carbodiimide) , DCC (dicyclohexylcarbodiimide) , BOP (benzotriazol-1-yloxy-tris (dimethylamino) -phosphonium hexafluorophosphate) , pyBOP ( (benzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate) , etc.
  • solvent refers to an individual solvent or to a mixture of solvents that result in the desired properties of the solvent mixture.
  • an aprotic organic solvent could be toluene, or it could be a mixture of toluene and another aprotic solvent such as DMF.
  • aprotic organic solvent could also encompass a toluene/DMF mixture.
  • a protic solvent could encompass water or a mixture of water and methanol.
  • a “protic solvent” is a solvent that has a hydrogen atom bound to a polar group, such as oxygen (as in a hydroxyl group) or nitrogen (as in an amine group) .
  • a protic solvent any solvent that contains labile H+ is called a protic solvent.
  • the molecules of such solvents readily donate protons (H+) to reagents.
  • protic solvents cannot easily donate hydrogen.
  • Aprotic solvents are usually classified as either polar aprotic or non-polar (or apolar) aprotic depending on the values of their dielectric constants.
  • Protic solvents are usually polar protic solvents and have high dielectric constants and high polarity.
  • protic solvents Some common characteristics of protic solvents are the ability to display hydrogen bonding, having acidic hydrogens (although they may be very weakly acidic such as ethanol) and that they are able to dissolve salts. Examples include water, most alcohols, formic acid, hydrogen fluoride, nitromethane, acetic acid and ammonia.
  • aprotic solvents Some common characteristics of aprotic solvents are that they can accept hydrogen bonds, do not have acidic hydrogen and are able to dissolve salts. These criteria are relative and very qualitative. A range of acidities are recognized for aprotic solvents. Their ability to dissolve salts depends strongly on the nature of the salt.
  • Polar aprotic solvents are solvents that will dissolve many salts. They lack an acidic hydrogen. Consequently, they are not hydrogen bond donors. These solvents generally have intermediate dielectric constants andpolarity. Although it discourages the use of the term "polar aprotic" , IUPAC describes such solvents as having both high dielectric constants and high dipole moments, an example being acetonitrile.
  • solvents meeting IUPAC's criteria include N,N-dimethylformamide (DMF) , N, N-dimethylacetamide (DMA) , N-methylpyrrolidone (NMP) , hexamethylphosporamide (HMPA) , tetrahydrofuran, ethyl acetate, acetone, acetonitrile (MeCN) , and dimethylsulfoxide (DMSO) .
  • DMF N,N-dimethylformamide
  • DMA N, N-dimethylacetamide
  • NMP N-methylpyrrolidone
  • HMPA hexamethylphosporamide
  • tetrahydrofuran ethyl acetate
  • MeCN acetonitrile
  • DMSO dimethylsulfoxide
  • Apolar or non-polar aprotic solvents usually have small dielectric constants.
  • non-polar aprotic solvents are hexane and other alkanes, benzene, toluene, 1, 4-dioxane, chloroform, ethers such as diethyl ether, dichloromethane, dichloroethane, etc.
  • equivalent refers to “molar equivalent” .
  • one equivalent of reagent A for each equivalent of reagent B means one mol of reagent A for each mol of reagent B is used in the reaction.
  • a mol is defined as the number that results when the total weight of a substance used is divided by the molecular weight of said substance, both weights being in the same units (for example, grams) .
  • the compounds of the invention are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound’s identity.
  • compounds of Formula I are compounds of Formula II.
  • compounds of Formula I are compounds of Formula III.
  • compounds of Formula I are compounds of Formula IV.
  • a first process for making a compound of Formula II, a compound of Formula III or a compound of Formula IV comprises the steps of:
  • a second process for making a compound of Formula II, a compound of Formula III or a compound of Formula IV comprises the steps of:
  • a third process for making a compound of Formula II, a compound of Formula III or a compound of Formula IV comprises the steps of:
  • a fourth process for making a compound of Formula II, a compound of Formula III or a compound of Formula IV comprises the steps of:
  • amidating carboxylic acid (8) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or a salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1)
  • a fifth process for making a compound of Formula III, or a compound of Formula IV comprises the steps of:
  • amidating carboxylic acid (8) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1) ;
  • a sixth process for making a compound of Formula IV comprises the steps of:
  • amidating carboxylic acid (8) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or a salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1) ;
  • R 1 is phenyl, or a 5 to 6-membered heteroaryl ring; optionally substituted with up to three instances independently selected from the group consisting of halogen or methyl; wherein said 5 or 6-membered heteroaryl ring contains up to 3 ring atoms selected from the group consisting of N, S or O;
  • R 2 is phenyl or a 6-membered heteroaryl, optionally substituted with up to three instances of R 5 ; wherein said 6-membered heteroaryl ring contains up to 2 nitrogen ring atoms;
  • R 4 is chloro, -OMe or -NR 6 R 7 ;
  • each R 5 is independently methyl, methoxy or halogen
  • R 6 is hydrogen or C 1-4 alkyl substituted with 0 to 3 instances of R 8 ;
  • R 7 is hydrogen or C 1-4 alkyl substituted with 0 to 3 instances of R 8 ;
  • each R 8 is independently –OH, C 1-3 haloalkyl, halogen or –C (O) NH 2 .
  • R 1 is phenyl. In other embodiments, R 1 is a 5 to 6-membered heteroaryl ring. In still other embodiments, R 1 is a 5-membered heteroaryl ring. In still other embodiments, R 1 is a 5-membered heteroaryl ring containing up to 2 ring heteroatoms selected from the group consisting of N and O. In still other embodiments, R 1 is a 5-membered heteroaryl ring containing up to 2 ring heteroatoms selected from the group consisting of N and O and it is unsubstituted.
  • R 2 is phenyl, optionally substituted with up to two instances of R 5 .
  • R 2 is a 6-membered heteroaryl, optionally substituted with up to two instances of R 5 ; wherein said 6-membered heteroaryl ring contains up to 2 nitrogen ring atoms.
  • R 2 is phenyl, optionally substituted with up to one instance of R 5 .
  • each R 5 is independently methyl or halogen. In other embodiments, each R 5 is independently halogen. In still other embodiments, each R 5 is fluoro.
  • R 6 is hydrogen or C 1-2 alkyl substituted with 0 to 3 instances of R 8 . In other embodiments, R 6 is hydrogen. In still other embodiments, R 6 is C 1-2 alkyl substituted with 2 instances of R 8 . In yet other embodiments, R 6 is C 1-2 alkyl substituted with 3 instances of R 8 .
  • R 7 is hydrogen or C 1-2 alkyl substituted with 0 to 3 instances of R 8 . In other embodiments, R 7 is hydrogen. In still other embodiments, R 7 is C 1-2 alkyl substituted with 2 instances of R 8 . In yet other embodiments, R 7 is C 1-2 alkyl substituted with 3 instances of R 8 .
  • each R 8 is independently –OH, trifluoromethyl, or –C (O) NH 2 .
  • R 1 is a 5-membered heteroaryl ring containing up to 2 ring heteroatoms selected from the group consisting of N and O and it is unsubstituted;
  • R 2 is phenyl, optionally substituted with one or two instances of R 5 ; each R 5 is fluoro;
  • R 6 is hydrogen;
  • R 7 is C 1-2 alkyl substituted with 3 instances of R 8 and each R 8 is independently –OH, trifluoromethyl, or –C (O) NH 2 .
  • a compound of Formula I is a compound of Formula V.
  • a compound of Formula I is a compound of Formula VI.
  • a compound of Formula I is a compound of Formula VII.
  • a first process for making a compound of Formula V, a compound of Formula VI or a compound of Formula VII comprises the steps of:
  • a second process for making a compound of Formula V, a compound of Formula VI or a compound of Formula VII comprises the steps of:
  • a third process for making a compound of Formula V, a compound of Formula VI or a compound of Formula VII comprises the steps of:
  • a fourth process for making a compound of Formula V, a compound of Formula VI or a compound of Formula VII comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or a salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ )
  • a fifth process for making a compound of Formula VI, or a compound of Formula VII comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • a sixth process for making a compound of Formula VII comprises the steps of:
  • bromopyrimidine intermediate (6) with an appropriate amount of ethynyltrimethylsilane, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable base, in the presence of an appropriate amount of an optional suitable Cu (I) catalyst and an appropriate amount of a suitable Pd catalyst to afford, after workup, a solution of intermediate (7) in a suitable solvent;
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • R 6 is hydrogen or C 1-2 alkyl substituted with 0 to 3 instances of R 8 . In other embodiments, R 6 is hydrogen. In still other embodiments, R 6 is C 1-2 alkyl substituted with 2 instances of R 8 . In yet other embodiments, R 6 is C 1-2 alkyl substituted with 3 instances of R 8 .
  • R 7 is hydrogen or C 1-2 alkyl substituted with 0 to 3 instances of R 8 . In other embodiments, R 7 is hydrogen. In still other embodiments, R 7 is C 1-2 alkyl substituted with 2 instances of R 8 . In yet other embodiments, R 7 is C 1-2 alkyl substituted with 3 instances of R 8 .
  • each R 8 is independently –OH, trifluoromethyl, or –C (O) NH 2 .
  • R 6 is hydrogen; R 7 is C 1-2 alkyl substituted with 3 instances of R 8 and each R 8 is independently –OH, trifluoromethyl, or -C (O) NH 2 .
  • a compound of Formula I is the compound of Formula IA.
  • a compound of Formula I is Formula IB.
  • a compound of Formula I is a compound of Formula IC.
  • a compound of Formula I is a compound of Formula ID.
  • a first process for making a compound of Formula IA, Formula IB, Formula IC or Formula ID comprises the steps of:
  • a second process for making a compound of Formula IA, Formula IB, Formula IC or Formula ID comprises the steps of:
  • a third process for making a compound of Formula IA, Formula IB, Formula IC or Formula ID comprises the steps of:
  • a fourth process for making a compound a compound of Formula IA, Formula IB, Formula IC or Formula ID comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • a fifth process for making a compound of Formula IA, Formula IB, Formula IC or Formula ID comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • a sixth process for making a compound of Formula IA comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • the compound of Formula IA can be further purified.
  • the preparation of purer compound of Formula IA involves the additional step of:
  • step vi) dissolving the compound of Formula IA obtained in step vi) in an appropriate amount of MeOH and stirring the resulting mixture at a temperature between 30°C and 65°C until all solids dissolve to obtain a methanol solution of Formula IA;
  • a sixth process for making the compound of Formula IB comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • a sixth process for making the compound of Formula IC comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • a sixth process for making the compound of Formula ID comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • a seventh process for making the compound of Formula IC comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • An eighth process for making the compound of Formula ID comprises the steps of:
  • amidating carboxylic acid (8’ ) by reacting it with an appropriate amount of oxalyl chloride or an equivalent amide coupling reagent, in a suitable aprotic organic solvent, at a suitable temperature, in the presence of an appropriate amount of a suitable catalyst; followed by an appropriate amount of N, O-dimethylhydroxylamine or salt (e.g. HCl salt) thereof, in the presence of an appropriate excess of a suitable base, at a suitable temperature, in a suitable solvent to afford amide (1’ ) ;
  • the compound of Formula ID can be obtained as a specific polymorph (Form B) .
  • the preparation of polymorph Form B of the compound of Formula ID involves the additional steps of:
  • step vi) dissolving the compound of Formula ID obtained in step vi) in acetonitrile and water at an appropriate temperature between 70 °C and 75 °C;
  • step B filtering the solution of step A” ) to form a filtered solution of the compound
  • step D cooling the slurry of step C” ) to a temperature between 0 °C and 5 °C to yield crystalline Form B of the compound of Formula ID;
  • An appropriate amount of intermediate amide (1’ ) or intermediate amide (1) is at least one equivalent of amide (1) or amide (1’ ) per equivalent of intermediate pyrimidine (2) . In some embodiments, an appropriate amount is between 0.95 and 1.2 equivalents of amide (1) or (1’ ) per 1 equivalent of the pyrimidine (2) . In other embodiments, it is between 1 and 1.1 equivalents. In other embodiments it is between 1 and 1.05 equivalents. In still other embodiments, it is one equivalent. In yet other embodiments, it is 1.05 equivalents.
  • a suitable aprotic organic solvent is, an anhydrous organic solvent, for example, THF or hexanes, or a mixture of THF and hexanes. Other suitable aprotic solvents are, for instance, 2-methyltetrahydrofuran or toluene.
  • a suitable temperature is below -40 °C. In some embodiments, a suitable temperature is between -90 °C and -40 °C. In some embodiments, a suitable temperature is one between -90 °C to -45 °C. In other embodiments, a suitable temperature is one between -90 °C to -50 °C. In some embodiments, a suitable temperature is between -90 °C to -60 °C. In some embodiments, a suitable temperature is between -80 °C to -60 °C. In some embodiments, a suitable temperature is between -78 °C to -60 °C. In other embodiments, a suitable temperature is between -65 °C to -55 °C. In still other embodiments, a suitable temperature is between -70 °C to -60 °C. In yet other embodiments, a suitable temperature is below -55 °C.
  • a suitable base is, for example, n-butyllithium.
  • Other suitable bases are sodium bis (trimethylsilyl) amide (NaHMDS) , lithium bis (trimethylsilyl) amide (LiHMDS) , potassium bis (trimethylsilyl) amide (KHMDS) , sodium hydride (NaH) , iso-propylmagnsium chloride (iPrMgCl) , methylmagnesium chloride (MeMgCl) and lithium diisopropylamide (LDA) .
  • Each of these bases is usually added to the reaction mixture in the form of a solution in an organic non-protic solvent.
  • n-butyllithium can be added as a solution in hexanes.
  • An appropriate amount of a suitable base is between 0.90 equivalent and 1.2 equivalents per each equivalent of intermediate (2) . In some embodiments, it is between 0.9 equivalent and 1.5 equivalents. In some embodiments, it is between 0.9 equivalent and 1.3 equivalents. In other embodiments, it is between 1.1 equivalents and 1.5 equivalents. In still other embodiments, it is between 1.1 equivalents and 1.4 equivalents. In yet other embodiments it is between 1.1 equivalents and 1.3 equivalents. In yet other embodiments it is 1 equivalent.
  • the reaction of intermediate amide (1) and pyrimidine (2) is quenched with an acid.
  • the acid is an aqueous acid, for example, hydrochloric acid.
  • the acid is non-aqueous acid, such as glacial acetic acid.
  • product intermediate (3) is isolated before the reaction of step ii) .
  • N, O-dimethylhydroxylamine is added as the HCl salt.
  • N, O-dimethylhydroxylamine hydrochloride is between 0 and 1.5 equivalents of N, O-dimethylhydroxylamine hydrochloride per equivalent of intermediate pyrimidine (2) .
  • an appropriate amount is between 0 and 1.0 equivalent.
  • an appropriate amount is between 0 and 1.4 equivalents.
  • an appropriate amount is between 0 and 1.2 equivalents.
  • it is between 0.1 and 0.9.
  • it is 0.6 or 0.5 equivalents.
  • no extra N, O-dimethylhydroxylamine is added in step ii) .
  • a suitable solvent is a protic or non-protic solvent.
  • protic solvents are, for example, water or an aqueous acid solution.
  • a suitable solvent that is an aqueous acid solution is, for example, an HCl solution, an AcOH solution, or an H 2 SO 4 solution.
  • no added acid needs to be used in this step and the quenching works when at least 1 equivalent of N, O-dimethylhydroxylamine hydrochloride is used alone, in the absence of added acid.
  • the acidic quenching is carried out with one of the acidic aqueous solutions listed above and in the absence of added hydroxylamine hydrochloride.
  • the solvent is a mixture of an aqueous acidic solvent with a non-protic solvent.
  • the solvent can be a mixture of aqueous HCl with ethyl acetate.
  • Other alternative solvents include, for instance 2-methylTHF, THF, MTBE, or mixtures of all the above suitable solvents thereof.
  • the solvent is an organic solvent or solvents, such as ethyl acetate, 2-methylTHF, THF, MTBE, or a mixture thereof.
  • the solvent is an acidic anhydrous organic solvent, such as glacial acetic acid.
  • the solvent is an organic solvent comprising anhydrous acid, such as glacial acetic acid.
  • a suitable temperature is between 0 °C and 30 °C. In some embodiments, a suitable temperature is between 0 °C and 25 °C. In other embodiments it is between 0 °C and 5 °C. In other embodiments it is between 5 °C and 30 °C. In other embodiments it is between 5 °C and 25 °C. In other embodiments it is between 10°C and 25 °C. In other embodiments it is between 15 °C and 25 °C.
  • the reaction mixture pH is adjusted after the solution obtained in step i) , containing intermediate (3’ ) , is added to the acidic reaction mixture, optionally containing N, O-dimethylhydroxylamine hydrochloride.
  • the reaction mixture may be acidic because of the presence of N, O-dimethylhydroxylamine hydrochloride or the presence of an added aqueous acid or both.
  • the acidic reaction mixture contains a non-aqueous acid in an organic solvent and optionally N, O-dimethylhydroxylamine hydrochloride.
  • the solution obtained in step i) is added to the acidic reaction mixture containing glacial acetic acid and N, O-dimethylhydroxylamine hydrochloride in ethyl acetate.
  • the solution obtained in step i) , containing intermediate (3’ ) is added to an acidic reaction mixture and optionally N, O-dimethylhydroxylamine or a salt thereof (e.g. HCl salt) is added after acidic quenching has already occurred.
  • the suitable pH > 5 may be obtained by addition of an aqueous base, for example, a saturated sodium bicarbonate solution or a saturated potassium bicarbonate solution or a similar base.
  • the optional added N, O-dimethylhydroxylamine or a salt (e.g. HCl salt) thereof may be added after the base, in other embodiments it may be added before the base.
  • a suitable resulting pH is any pH above 5 and below 9.
  • a suitable pH is above 6 and below 9.
  • a suitable pH is above 7 and below 9.
  • a suitable pH is between 6.5 and 9.
  • the pH of the mixture is adjusted to a pH of between 7 and 8.
  • a suitable pH is between 6.5 and 8.5.
  • the suitable pH is between 6.75 and 8.25.
  • a suitable pH is between 6.5 and 9.
  • the hydrazine is used in the form of a salt. In some embodiments, it is the hydrochloride salt.
  • an appropriate amount of a hydrazine of formula R 2 -CH 2 -NH-NH 2 or a salt (e.g. HCl salt) thereof is at least one equivalent of hydrazine per each equivalent of intermediate (4) or intermediate (4’ ) .
  • an appropriate amount of hydrazine is between 1 equivalent and 2 equivalents. In other embodiments, it is between 1 equivalent and 1.5 equivalent. In still other embodiments, it is between 1 equivalent and 1.3 equivalents. In still other embodiments, it is between 1.1 equivalents and 1.4 equivalents. In still other embodiments it is between 1.1 equivalents and 1.3 equivalents. In yet other embodiments it is 1.2 equivalents.
  • An optional suitable base is, for instance, potassium carbonate (K 2 CO 3 ) .
  • Other optional suitable bases in this step are, for example, sodium acetate (NaOAc) , sodium carbonate (Na 2 CO 3 ) , sodium hydrogen carbonate (NaHCO 3 ) and potassium bicarbonate (KHCO 3 ) .
  • An appropriate amount of a suitable base is an amount that will partially or totally neutralize the acid from the hydrazine hydrochloride, when the hydrochloride form of the hydrazine is used. For instance, 0.5 to 1.1 equivalents of base per each equivalent of hydrazine hydrochloride. In other embodiments, an appropriate amount is 0.5 to 0.9 equivalents. In still other embodiments, it is 0.65 equivalents. In yet other embodiments, it is 0.6 equivalents. In still other embodiments it is between 0.9 and 1.1 equivalents.
  • a suitable solvent is, for instance, absolute ethanol or isopropanol.
  • Other protic or aprotic solvents that may be used in this step are, for example dichloromethane, THF, CH 3 CN and methanol.
  • the base When an optional suitable base is used, the base will be dissolved or suspended in water before mixing it with the hydrazine hydrochloride dissolved in the suitable protic or aprotic solvent.
  • the mixture of the hydrazine hydrochloride and optional suitable base in a protic or aprotic solvent and water will then be mixed with a solution of the intermediate (4) or (4’ ) in the suitable protic or aprotic solvent. Therefore, the reaction in this case will be run in a mixture of a protic or aprotic solvent and water.
  • a suitable temperature is between 10 °C and 40 °C. In other embodiments, a suitable temperature is between 15 °C and 30 °C. In some embodiments, it is between 10 °C and 30 °C. In other embodiments, it is between 15°C and 30 °C. In other embodiments, it is between 15 °C and 25 °C. In still other embodiments, it is between 20 °C and 25 °C.
  • a suitable methoxide salt is, for example, MeONa, MeOLi, MeOK, MeOCs, or similar methoxides, and MeOH or a suitable aprotic solvent is used as the solvent.
  • a suitable base is, for example, K 2 CO 3 , Na 2 CO 3 , Cs 2 CO 3 , KHCO 3 or similar bases, and then MeOH is used as the solvent.
  • the dibromopyrimidine compound of formula (5) is reacted with a methoxide salt (e.g., MeONa) in methanol.
  • An appropriate amount of the suitable base is at least one equivalent of the base for each equivalent of dibromopyrimidine (5) . In other embodiments it is between 0.9 and 1.2 equivalents. In other embodiments, it is between 1 and 1.1 equivalents. In other embodiments it is 1.01 equivalents of the base for each equivalent of dibromopyrimidine (5) . In other embodiments it is 1.02 equivalents of base for each equivalent of dibromopyrimidine (5) .
  • a suitable aprotic solvent when MeOH is not the solvent is, for example THF or a similar solvent.
  • a suitable temperature is between -25 °C and 15 °C. In some embodiments, a suitable temperature is between -20 °C and 10 °C. In other embodiments, it is between-15 °C and 5 °C.In still other embodiments, it is between -15 °C and 0 °C. In still other embodiments, it is between -20 °C and 5 °C. In still other embodiments, it is between -15 °C and 5 °C. In yet other embodiments, it is between -15 °C and -5 °C.
  • a suitable aprotic solvent in which the intermediate pyrimidine (6) in carried to the next step is, for example an ether.
  • the ether is methyl-tert-butyl ether.
  • a suitable aprotic solvent is, for example, CH 2 Cl 2 , EtOAc, THF, toluene or a similar solvent.
  • An appropriate amount of ethynyltrimethylsilane is at least one equivalent of ethynyltrimethylsilane per equivalent of intermediate (6) generated in the previous step.
  • an appropriate amount of ethynyltrimethylsilane is between 1.0 and 2.0. In other embodiments, it is between 1 and 1.8 equivalents. In other embodiments, it is between 1 and 1.6 equivalents. In still other embodiments it is between 1 and 1.5 equivalents. In still other embodiments it is between 1 and 1.3 equivalents. In other embodiments it is between 1.0 equivalents and 1.2 equivalents. In yet other embodiments it is 1.2 equivalents.
  • a suitable aprotic organic solvent is, for example, an ether.
  • the ether is methyl-tert-butyl ether.
  • a suitable aprotic solvent is for example EtOAc, THF, toluene, CH 2 Cl 2 or a similar solvent.
  • a suitable temperature is between 15 °C and 40 °C. In one embodiment, a suitable temperature is between 15 °C and 35 °C. In other embodiments, it is between 15 °C and 30 °C. In other embodiments, it is between 18 °C and 30 °C. In still other embodiments, it is between 20 °C and 30 °C. In yet other embodiments, a suitable temperature is 25 °C.
  • a suitable base is, for example, triethylamine, Hunig’s base, Et 2 NH, iPr 2 NH, piperidine, pyrrolidine, K 2 CO 3 , Na 2 CO 3 , Cs 2 CO 3 , K 3 PO 4 or similar.
  • An appropriate amount of a suitable base is at least 1 equivalents of the suitable base for each equivalent of intermediate pyrimidine (6) . In some embodiments it is between 1 and 10 equivalents. In other embodiments, it is between 1 and 5 equivalents. In other embodiments, it is between 1 and 3 equivalents. In still other embodiments it is between 1.5 and 2.5 equivalents. In still other embodiments, it is 2 equivalents. In yet other embodiments, the appropriate amount of a suitable base could be a large excess, for example, the base could be used as the solvent in the reaction.
  • a suitable optional Cu (I) salt is, for example, CuCl, CuBr, CuI or CuOTf.
  • the reaction can be carried out without copper catalyst (copper free conditions) .
  • An appropriate amount the Cu (I) salt is a catalytic amount.
  • a catalytic amount can be any amount below 1 equivalent of the Cu (I) salt for each equivalent of intermediate pyrimidine (6) .
  • the catalytic amount is between above 0 and below 1 equivalents.
  • the catalytic amount is between above 0 and below 0.75 equivalents. In other embodiments it is between 0 and 0.5 equivalents, or between 0 and 0.25 equivalents, or between 0 and 0.1 equivalents, or between 0 and 0.01 equivalents.
  • a catalytic amount of the Cu (I) salt is, for example between 0.0025 and 0.006 equivalents of Cu (I) salt per each equivalent of intermediate pyrimidine (6) .
  • a catalytic amount of Cu (I) salt is between 0.003 and 0.006 equivalents. In other embodiments, it is between 0.004 and 0.006 equivalents. In other embodiments it is 0.005 equivalents.
  • a suitable Pd catalyst is, for example, PdCl 2 (PPh 3 ) 2 .
  • Other suitable Pd catalyst include Pd(OAc) 2 , Pd (PPh 3 ) 4 , PdCl 2 (dppf) , Pd (dppe) Cl and Pd (dppp) Cl 2 .
  • An appropriate amount of a suitable Pd catalyst is a catalytic amount.
  • a catalytic amount of a Pd catalyst is, for example, between 0 and 0.2 equivalents of Pd per each equivalent of intermediate (6) .
  • a catalytic amount is between 0 and 0.1 equivalents. In still other embodiments, it is between 0 and 0.01 equivalents. In still other embodiments, it is between 0.0010 and 0.0040 equivalents of Pd per each equivalent of intermediate pyrimidine (6) .
  • a catalytic amount is between 0.0015 and 0.0030 equivalents. In other embodiments it is between 0.0020 and 0.0030 equivalents. In still other embodiments, it is 0.0025 equivalents.
  • a suitable solvent in which the intermediate pyrimidine (7) in carried to the next step is, for example an ether.
  • the ether is methyl-tert-butyl ether.
  • the suitable solvent is, for example, Hunig’s base, Et 2 NH, iPr 2 NH, piperidine, pyrrolidine, THF, Toluene, CH 2 Cl 2 , CH 3 CN, DMF, DMSO or similar solvents.
  • the intermediate pyrimidine (6) is reacted with ethynyltrimethylsilane in methyl-tert-butyl ether in the presence of trimethylamine, Pd (PPh 3 ) 2 Cl 2 catalyst and CuI.
  • the de-silylation may carried out with a suitable fluoride reactant, a suitable acid or a suitable base.
  • a suitable fluoride reactant is, for example, KF, TBAF, CsF or NaF, among others.
  • a suitable fluoride reactant is KF.
  • a suitable acid is, for example, HCl, HBr, MeSO 3 H, HF, or similar aqueous acids.
  • a suitable base is, for example, MeONa, MeOK, MeOCs, K 2 CO 3 , Na 2 CO 3 , Cs 2 CO 3 , or similar bases.
  • An appropriate amount of a suitable fluoride reactant, suitable acid or suitable base is a catalytic amount.
  • a catalytic amount of the suitable fluoride reactant, suitable acid or suitable base is, for example, less than one equivalent of the suitable fluoride reactant, suitable acid or suitable base per each equivalent of intermediate (7) .
  • a catalytic amount is between 0.01 equivalents and 1. In other embodiments, it is between 0.01 and 0.75. In other embodiments, it is between 0.01 and 0.5. In other embodiments, it is between 0.01 and 0.25. In still other embodiments, it is between 0.01 and 0.1. In still other embodiments, it is between 0.01 and 0.05. In another embodiment, it is between 0.015 and 0.03. In still other embodiments, it is between 0.015 and 0.025. In other embodiments it is 0.02 equivalents.
  • a suitable solvent is, for example MeOH, THF, CH 3 CN, EtOAc, CH 2 Cl 2 , CHCl 3 , or many others, depending on the fluoride reactant, acid or base used.
  • the suitable solvent is MeOH.
  • a suitable temperature is between 15 °C and 35 °C. In one embodiment, a suitable temperature is between 15 °C and 30 °C. In other embodiments, it is between 18 °C and 30 °C.
  • a suitable equivalent reagent to oxalyl chloride is, for instance thionyl chloride or 1-Ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDAC) .
  • An appropriate amount of oxalyl chloride or equivalent reagent is at least one equivalent of oxalyl chloride per equivalent of carboxylic acid (8) or (8’ ) . In some embodiments, an appropriate amount is between 1 and 3 equivalents. In other embodiments, an appropriate amount is between 1 and 2 equivalents. In still other embodiments, an appropriate amount is between 1 and 1.5 equivalents. In yet other embodiments, an appropriate amount is between 1.1 and 1.3 equivalents. In yet other embodiments, an appropriate amount is 1.1 equivalents or 1.2 equivalents.
  • a suitable aprotic organic solvent is, for instance toluene.
  • Other suitable solvents are, for example methylene chloride or tetrahydrofuran.
  • a suitable catalyst is DMF.
  • An appropriate amount of the suitable catalyst is a catalytic amount, i.e., less than one equivalent of catalyst per each equivalent of starting material (8) or starting material (8’ ) .
  • an appropriate amount is between 0.01 and 0.09 equivalents. In other embodiments it is between 0.01 and 0.07 equivalents. In still other embodiments, it is between 0.02 and 0.07 equivalents. In still other embodiments it is between 0.04 and 0.06 equivalents. In yet other embodiments, it is 0.05 equivalents.
  • a suitable temperature for the reaction of starting material (8) or starting material (8’ ) with oxalyl chloride or thionyl chloride is a temperature between 40 °C and 95 °C. In some embodiments, it is between 40 °C and 80 °C. In other embodiments it is between 40 °C and 55 °C. In some embodiments, a suitable temperature is between 45 °C and 55 °C. In other embodiments, it is a temperature of between 45 °C and 50 °C. In other embodiments, it is a temperature of between 50 °C and 60 °C.
  • a suitable temperature for the reaction of starting material (8) or starting material (8’ ) with EDAC is a temperature between -10 °C and 25 °C. In some embodiments, a suitable temperature is between -10 °C and 20 °C. In some embodiments, a suitable temperature is between -10 °C and 0 °C. In some embodiments, a suitable temperature is between -10 °C and -5 °C.
  • the N, O-dimethylhydroxylamine is used as the HCl or hydrochloride salt.
  • N, O-dimethylhydroxylamine hydrochloride is at least one equivalent of N, O-dimethylhydroxylamine hydrochloride per each equivalent of starting material (8) or starting material (8’ ) .
  • an appropriate amount of N,O-dimethylhydroxylamine hydrochloride is between 1 equivalent and 2 equivalents per each equivalent of starting material (8) or starting material (8’ ) .
  • it is between 1 equivalent and 1.5 equivalents.
  • it is between 1 equivalent and 1.2 equivalents.
  • it is between 1.1 equivalents and 1.2 equivalents.
  • a suitable base is, for instance, K 2 CO 3 or NaOH.
  • Other suitable bases are, for example, NaHCO 3 , KHCO 3 , Et 3 N, or Hunig’s base.
  • An appropriate excess of said suitable base is at least 2 equivalents of base per equivalent of N, O-dimethylhydroxylamine hydrochloride used. In some embodiments, an appropriate amount is between 2 and 5 equivalents of base per equivalent of N, O-dimethylhydroxylamine hydrochloride. In other embodiments, it is 2 to 3 equivalents. In still other embodiments, it is between 2 and 4 equivalents.
  • a suitable solvent for the water/aprotic solvent mixture is, for instance, dichloromethane (DCM) .
  • DCM dichloromethane
  • Other suitable solvents are, for example, ethyl acetate, tetrahydrofuran and 2-methyltetrahydrofuran.
  • the reaction can be carried out under suitable acidic, basic or neutral conditions.
  • a suitable aqueous acid is, for example, HCl.
  • Other acids that could be used include, for instance, methylsulfonic acid (MeSO 3 H) or HBr.
  • a suitable reagent that could be used under basic conditions is, for example, MeSNa.
  • a suitable reagent that could be used under neutral and anhydrous conditions is, for example, BBr 3 .
  • step iv De-methylation reactions such as step iv) are common and many different conditions may be found in the literature.
  • An appropriate amount of acid is between 3 and 6 equivalents of acid per equivalent of compound of Formula II or compound of Formula V. In some embodiments, an appropriate amount is between 4 and 6 equivalents. In other embodiments, it is between 4.5 equivalents and 6 equivalents. In still other embodiments, it is 4.90 to 5 equivalents.
  • HCl can be provided, for instance, in the form of concentrated HCl (e.g., 37 wt %HCl) .
  • a suitable protic solvent is, for instance, MeOH.
  • Other suitable protic solvents are EtOH and iPrOH.
  • a suitable aprotic solvent is for example an ether or THF.
  • a suitable temperature is between 50 °C and 70 °C. In some embodiments, a suitable temperature is between 55 °C and 65 °C. In still other embodiments, a suitable temperature is between 60 °C and 65 °C. In still other embodiments, a suitable temperature is between 62°C and 65 °C.
  • An appropriate amount of POCl 3 is at least two equivalents of POCl 3 per each equivalent of intermediate (9) or intermediate (9’ ) used. In some embodiments, an appropriate amount of POCl 3 is at least 4 equivalents. In some embodiments, an appropriate amount is at least 3 equivalents. In some embodiments, an appropriate amount is at least 2 equivalents. In some embodiments, an appropriate amount is at least 1 equivalent. In still other embodiments, an appropriate amount is between 1 and 4 equivalents of POCl 3 per each equivalent of intermediate (9) or intermediate (9’ ) .
  • a suitable temperature is between 50 °C and 90 °C. In some embodiments, a suitable temperature is between 60 °C and 90 °C. In some embodiments, a suitable temperature is between 65 °C and 90 °C. In other embodiments, a suitable temperature is between 70 °C and 90 °C. In still other embodiments, a suitable temperature is between 75 °C and 90 °C. In yet other embodiments, a suitable temperature is between 75 °C and 85 °C. In other embodiments, a suitable temperature is between 75 °C and 80 °C.
  • a suitable aprotic organic solvent is, for instance, acetonitrile (CNMe) .
  • the reaction can also be carried out in neat POCl 3 , in the absence of any solvents.
  • a suitable optional base is, for instance, N, N-dimethylaniline.
  • the reaction also works in the absence of a base.
  • An appropriate amount of a suitable base when one is used, is between 0.2 and 2 equivalents of base per each equivalent of intermediate (9) or intermediate (9’ ) used. In some embodiments, an appropriate amount of base is between 1.3 and 1.6 equivalents. In some embodiments, an appropriate amount of base is between 1.2 and 1.8 equivalents. In other embodiments, it is 1 equivalent.
  • an appropriate amount of an amine (10) , or an amine (13) , or an amine malic acid salt (14) or an amine malic acid salt (18) or an amine (15A) or its corresponding HCl salt (15) , or an amine (19A) or its corresponding HCl salt (19) is at least one equivalent of the amine or HCl or malic acid salt per each equivalent of compound of Formula VI or compound of Formula III.
  • an excess of amine may be used.
  • an amount between 1 and 5 equivalents of the amine can be used.
  • the appropriate amount is between 1 and 4 equivalents. In other embodiments, it is between 1 and 3 equivalents. In still other embodiments, it is between 1 and 2 equivalents. In still other embodiments it is between 1.1 and 1.5 equivalents. In yet other embodiments it is 1.1 to 1.3 equivalents.
  • a suitable optional base is, for instance, Hunig’s base.
  • Other suitable optional bases are, for example, Et 3 N, NaHCO 3 , and KHCO 3 .
  • An appropriate amount of an amine (10) , or an amine (13) , or an amine (15A) or an amine (19A) themselves may also be used as the base when they are in used in excess.
  • An appropriate amount of a suitable optional base is at least one equivalent of optional base per each equivalent of intermediate of Formula VI or intermediate of Formula III. In some embodiments, an appropriate amount is 2 equivalents.
  • a suitable solvent is dimethylsulfoxide (DMSO) .
  • DMSO dimethylsulfoxide
  • suitable solvents are, for instance, N,N-dimethylformamide (DMF) , N, N-dimethylacetamide (DMA) , and tert-butanol (t-BuOH) .
  • a suitable temperature is between 90 °C and 135 °C. In some embodiments, a suitable temperature is between 120 °C and 130 °C. In other embodiments, a suitable temperature is between 125 °C and 130 °C. In other embodiments, a suitable temperature is between 90 °C and 105 °C. In still other embodiments, it is between 95 °C and 104 °C
  • Novel intermediates that are useful in the processes described herein are also disclosed.
  • the present invention is directed to a compound of formula (3) or (4) .
  • R 1 is a 5-membered heteroaryl ring.
  • R 1 is an unsubstituted 5-membered heteroaryl ring containing up to 2 ring heteroatoms selected from the group consisting of N and O.
  • the present invention is directed to a compound of formula (3’ ) or (4’ ) .
  • the present invention is directed to a compound of formula (14) , (18) , (15) , (19) , (20) or (21) .
  • the present invention provides crystalline Form A of the compound of Formula IA.
  • Form A can be prepared according the process described herein, for example, the process of the 13 th specific embodiment, the first, second, third, fourth, fifth or sixth process for making the compound of Formula IA described above.
  • Form A is characterized by X-ray powder diffraction (XRPD) analysis.
  • XRPD X-ray powder diffraction
  • Form A of the compound of Formula IA has XRPD pattern substantially similar to those shown in FIG. 1.
  • Form A has XRPD pattern as shown in FIG. 1.
  • Form A has XRPD peaks as indicated in the table below:
  • Form A is characterized as having one, two, three, four, five, six, seven or eight major peaks in XRPD pattern selected from 4.2, 9.1, 9.8, 17.2, 17.7, 18.2, 27.5, and 36.0 degree 2 ⁇ angles.
  • Form A is characterized as having one, two, three, four or five major XRPD peaks selected from 4.2, 9.1, 9.8, 17.7, 18.2, and 36.0 degree 2 ⁇ angles.
  • Form A has major XRPD peaks at 9.1, 9.8, 17.7, and 18.2 degree 2 ⁇ angles.
  • Form A has major XRPD peaks at 4.2, 9.1, 9.8, 17.7, 18.2, and 36.0 degree 2 ⁇ angles.
  • Form A has major XRPD peaks at 4.2, 9.1, 9.8, 17.2, 17.7, 18.2, 27.5, and 36.0 degree 2 ⁇ angles. It is to be understood that a specified 2 ⁇ angle means the specified value ⁇ 0.1°.
  • major peaks refers to an XRPD peak with relative intensity of greater than 10%. Relative intensity is calculated as a ratio of the peak intensity of the peak of interest versus the peak intensity of the largest peak.
  • Form A can also be characterized by differential scanning calorimetry (DSC) .
  • Form A has an endothermic onset (i.e., a melting point) at a temperature between 140 °C and 180 °C, between 155 °C and 170 °C, between 160 °C and 170 °C, between 160 °C and 165 °C, between 162 °C and 164 °C, or between 162.5 °C and 163.5 °C.
  • the endothermic onset is at 163.1 °C. It is to be understood that a specified temperature means the specified value ⁇ 0.5 °C.
  • Form A is at least 70%, 80%, 90%, 95%, 98%, 99%, 99.5%, or 99.9%pure.
  • the purity of Form A is determined by diving the weight of Form A of the compound of Formula IA in a composition comprising the compound of Formula IA over the total weight of the compound of Formula IA in the composition.
  • a composition of the compound of Formula IA has at least 70%, 80%, 90%, 95%, 98%, 99%, 99.5%, or 99.9%by weight of the compound is the crystalline Form A of the compound.
  • each range is intended to be a shorthand format for presenting information, where the range is understood to encompass each discrete point within the range as if the same were fully set forth herein.
  • A.Solvent A 0.1%TFA in water (i.e. 1 mL in 1 L of water)
  • Step d) Coupling of Compound (8’ ) and N, O-Dimethylhydroxylamine to provide N-methoxy-N-methylisoxazole-3-carboxamide (1’ ) .
  • Oxalyl chloride (4.80 kg, 37.8 mol, 1.11 equiv) was charged via the addition funnel over the course of 4 hours 30 minutes, while maintaining the reaction temperature between 45 to 55 °C. Vigorous gas evolution was observed. A brown mixture was obtained after the addition. The brown mixture was held at 45 to 55 °C for 30 minutes, then heated to 85 to 95 °C and stirred at 85 to 95 °C for 1 hour. During heating, the brown mixture turned into a black mixture. The black mixture was cooled to 20 to 25 °C, over 4 hours and held at 20 to 25 °C for a minimum of 16 hours.
  • the reaction was monitored by quenching a portion of the reaction mixture into piperidine and monitoring the formation of the piperidine amide by HPLC ( (8’ ) : piperidine amide area: area %was ⁇ 1.9) .
  • HPLC HPLC
  • the dark mixture was in-line filtered via gas a dispersion tube (coarse frit) into a 20 L rotavapor flask.
  • Toluene (3.9 L) was used to rinse the reactor and the rinse was in-line filtered into the 20 L rotavapor flask.
  • the filtered reaction mixture was concentrated under reduced pressure until no more distillate was seen coming off.
  • the acyl chloride intermediate formed above (4.4 kg) was charged to a 100 L jacketed reactor containing N, O-dimethylhydroxylamine in dichloromethane, with stirring rate set at 210 RPM, while maintaining the reaction temperature between -10 to 0 °C, over 30 minutes. The addition was a little exothermic, and a brown mixture was obtained after the addition. The reaction mixture was stirred at -10 to 0 °C for 20 minutes, then warmed to 15 to 25 °C and stirred for 10 minutes at this temperature. The layers were separated. The bottom organic layer was collected, and the top aqueous layer was extracted with dichloromethane (7.7 L) .
  • the combined organic layers were transferred to a 100 L jacketed reactor and washed with a 15 wt %aqueous sodium chloride solution (11.6 L) . The layers were separated. The bottom organic layer was collected, and the top aqueous layer was extracted with dichloromethane (3.9 L) . The combined organic layers were concentrated under reduced pressure until no more distillate was seen coming off.
  • Tetrahydrofuran (7.7 L) was charged to this dark oil and the resulting mixture concentrated under reduced pressure to furnish intermediate (1’ ) as a dark oil (4.6 kg, 83 %corrected yield for THF, 4 wt %THF content by 1 H-NMR, 0.01 wt %water content by Karl-Fisher (KF) analysis, 98.9 %pure by HPLC) .
  • 1 H-NMR 500 MHz, CDCl 3 ) ⁇ ppm 8.48 (s, 1 H) ; 6.71 (s, 1 H) ; 3.78 (s, 3 H) ;3.38 (s, 3 H) .
  • Step a) substitution of Compound (5) with methoxide to provide 2-bromo-5-fluoro-4-methoxypyrimidine (6) .
  • Methyl t-butyl ether (51.4 L) was charged to the concentrated reaction mixture and the layers were allowed to separate over 1 hour. The organic layer was filtered via gas dispersion tube (coarse frit) and concentrated under reduced pressure to a volume of 19.3 L. Water was azeotropically removed under reduced pressure via continuously feeding methyl t-butyl ether (24.0 L) . The final volume was 18.0 L and the azeotropic removal of water was complete by KF analysis (0.24 wt %water content, acceptance criteria: ⁇ 0.4 wt %water content) . Intermediate (6) in methyl t-butyl ether was obtained as a light brown solution and used directly in the next step. 1 H-NMR (500 MHz, CDCl 3 ) ⁇ ppm 8.08 (s, 1 H) ; 4.04 (s, 3 H) .
  • Step b) coupling of Compound (6) and Ethynyltrimethylsilane to provide 5-fluoro-4-methoxy-2- ( (trimethylsilyl) ethynyl) pyrimidine (7) .
  • reaction mixture was cooled to 5 to 15 °C. Then 2 N HCl (16.0 L, 32.0 mol, 1.3 equiv) was charged over 4 minutes, while maintaining the reaction temperature below 25 °C(batch temperature increased from 6 °C to 22 °C) . The layers were allowed to separate over 20 min. The pH of the aqueous layer was ⁇ 1-2 by pH paper and it was discarded.
  • Methyl t-butyl ether was solvent exchanged to methanol under reduced pressure via continuously feeding methanol (25.6 L) and the final volume after solvent exchange was 19.2 L.
  • Intermediate (7) in methanol was obtained as a light brown solution and used directly in the next step.
  • 1 H-NMR 500 MHz, CDCl 3 ) ⁇ ppm 8.09 (s, 1 H) ; 3.94 (s, 3 H) ; 0.12 (s, 9 H) .
  • Step c) de-silylation of Compound (7) to provide 2-ethynyl-5-fluoro-4-methoxypyrimidine (2) .
  • Methyl t-butyl ether (32.1 L) was charged to the slurry and the layers were allowed to separate over 30 minutes. The top organic layer was collected, and the bottom aqueous layer was extracted with methyl t-butyl ether (12.8 L) . The combined organic layers were concentrated under reduced pressure to a volume of 19.3 L. The concentrate was filtered through a silica pad (960 g) and the silica pad was rinsed with additional methyl t-butyl ether (12.8 L) . The filtrate was collected and concentrated under reduced pressure to a volume of 19.3 L. Methyl t-butyl ether was solvent exchanged to heptane under reduced pressure via continuously feeding heptane (33.4 L) .
  • Steps i) and ii) coupling of Compounds (2) and (1’ ) to provide (E) -3- (5-fluoro-4-methoxypyrimidin-2-yl) -1- (isoxazol-3-yl) -3- (methoxy (methyl) amino) prop-2-en-1-one (4’ ) .
  • N, O-Dimethylhydroxylamine hydrochloride 0.586 kg, 6.0 mol, 0.5 equiv
  • 1 N HCl 9.6 L, 9.6 mol, 0.8 equiv
  • the reaction solution was cooled to 0 to 5 °C.
  • the above dark reaction solution from the 50 L round bottom flask was transferred to the 100 L jacketed reaction vessel over 15 minuteswith vigorously mixing.
  • Ethyl acetate (18.3 L) was used to rinse the 50 L round bottom flask and the rinse transferred to the 100 L jacketed reaction vessel.
  • the organic layer was filtered via gas dispersion tube (coarse frit) and concentrated under reduced pressure to a volume of 9.1 L.
  • Ethyl acetate was azeotropically removed under reduced pressure via continuously feeding methanol (18.3 L) .
  • the final volume after solvent exchange was 9.1 L and a slurry was obtained.
  • the resulting slurry was cooled to 0 to 5 °C and stirred at 0 to 5 °C for 30 minutes.
  • the resulting slurry was filtered, and the filter cake was washed with pre-cooled 0 to 5 °C methanol (2.7 L) .
  • Step iii) cyclization of Compound (4’ ) and 2-fluorobenzylhydrazine to provide 3- (3- (5-fluoro-4-methoxypyrimidin-2-yl) -1- (2-fluorobenzyl) -1H-pyrazol-5-yl) isoxazole (Formula V) .
  • 2-Fluorobenzylhydrazine hydrochloride (3.37 kg, 19.1 mol, 1.2 equiv) and methanol (9.8 L) were mixed in a 50 L round bottom flask equipped with an overhead stirrer and a thermocouple. The reaction mixture was stirred at 10 to 25 °C until most solids dissolved.
  • potassium carbonate (1.32 kg, 9.6 mol, 0.6 equiv) was charged to a suitable reaction vessel and dissolved in water (3.4 L) . The potassium carbonate solution was charged to the 50 L round bottom flask containing 2-fluorobenzylhydrazine hydrochloride solution between 10 to 25 °C, over 5 minutes, and a slurry was obtained.
  • Step iv) demethylation of Formula V to provide 5-fluoro-2- (1- (2-fluorobenzyl) -5- (isoxazol-3-yl) -1H-pyrazol-3-yl) pyrimidin-4-ol (9’ ) .
  • Step v) chlorination of Compound (9’ ) to provide 3- (3- (4-chloro-5-fluoropyrimidin-2-yl) -1-(2-fluorobenzyl) -1H-pyrazol-5-yl) isoxazole (Formula VI) .
  • Step I) amination of Compound (16) to provide 2- (aminomethyl) -1, 1, 1, 3, 3, 3-hexafluoropropan-2-ol (17) .
  • Ammonium hydroxide 28-30% (as NH 3 ) solution in water, 1.75 L, 26.8 mol, 9.6 equiv
  • methyl t-butyl ether 1.75 L
  • the condenser temperature was set to be -20 °C and to minimize the evaporation loss of both ammonia gas and (16) ) .
  • n-Heptane (1.8 L) was added and the mixture was concentrated under reduced pressure (jacket temperature not more than 20 °C and the vacuum torr 100) to bring the volume to 1.5 L.
  • the slurry was cooled to 0 to 5 °C and stirred at 0 to 5 °C for 30 minutes.
  • the resulting slurry was filtered, and the filter cake was washed with n-heptane (500 mL) .
  • the solid was air dried in a hood at 20 to 25 °C for 10 hours until constant weight to provide intermediate (17) as a white solid (383 g, 70%yield, 99%pure by GC) .
  • 1 H NMR 500 MHz, MeOD
  • ppm 3.09 (s, 2 H) ppm 3.09 (s, 2 H) .
  • Step vi) coupling of Formula VI and Compound (17) to provide 1, 1, 1, 3, 3, 3-hexafluoro-2-( ( (5-fluoro-2- (1- (2-fluorobenzyl) -5- (isoxazol-3-yl) -1H-pyrazol-3-yl) pyrimidin-4-yl) amino) methyl) propan-2-ol (FormulaIA) .
  • reaction mixture was transferred to a 100 L jacketed reaction vessel equipped with a nitrogen inlet-outlet, thermocouple, condenser, and overhead stirrer.
  • Toluene (11.2 L) , n-heptane (22.4 l) and Hunig’s base (0.64 L, 3.68 mol, 0.5 equiv) were then charged to reaction mixture.
  • the reaction mixture was heated to 40 to 50 °C.
  • Water (4.2 L) was added to the vigorously stirred reaction mixture (300 RPM) at 40 to 50 °C, over 2 hours, and the reaction mixture was stirred at 40 to 50 °C for 30 minutes to form the seed bed.
  • Step II recrystallization of the compound of Formula IA to provide purer compound of Formula IA (corresponds to steps A’ ) , B’ ) , C’ ) , D’ ) and E’ ) in the process of preparing compound of Formula IA or in the 13 th specific embodiment described above)
  • Methanol (12.0 L) was added to the 100 L jacketed reaction vessel to bring the volume to 68.0 L.
  • the reaction mixture was then heated to 55 to 65 °C, and water (29.2 L) was charged over 1 hour 30 minutes, while maintaining the batch temperature at 50 to 60 °C.
  • the resulting slurry was cooled to 20 to 25 °C, over 2 hours and held at 20 to 25 °C for 1 hour.
  • the slurry was filtered, and the filter cake was washed with a pre-mixed solution of methanol and water (19.5 L/19.5 L) .
  • Crystallinity of the compound of Formula IA prepared according to procedure described above_ was determined by XRPD.
  • the XPRD pattern is provided in FIG. 1.
  • the melting range by differential scanning calorimetry was also determined. DSC analysis was performed in a sealed pan with the temperature increased at a rate of 10 °C/min up to 300 °C. The DSC profile is shown in FIG. 2 and indicates a melting point of 163.1 °C.
  • Step A) cyanation of Compound (10) to provide racemic mixture 2- (bromomethyl) -3, 3, 3-trifluoro-2- ( (trimethylsilyl) oxy) propanenitrile (11) .
  • Trimethylsilanecarbonitrile (3.41 kg, 34.4 mmol, 0.97 equiv) and triethylamine (0.100 L, 0.073 kg, 0.72 mol, 0.02 equiv) were mixed in a 30 L jacketed reactor. The mixture was cooled to 10-15 °C. 3-Bromo-1, 1, 1-trifluoropropan-2-one ( (10) , 6.74 kg, 35.3 mol, 1.0 equiv) was charged via an addition funnel over 1 hour 40 minutes, while maintaining the reaction temperature between 0 to 20 °C. The reaction mixture was stirred at 20 to 25 °C for 1 hour.
  • Step B) conversion of nitrile racemic mixture (11) to amide to provide racemic mixture 2-(bromomethyl) -3, 3, 3-trifluoro-2-hydroxypropanamide (12) .
  • Concentrated sulfuric acid (8.6 L, 158mol, 4.5 equiv) was stirred in a 100 L jacketed reactor.
  • the sulfuric acid was heated to 40 to 45 °C, then the above intermediate (11) (racemic) was added via an addition funnel over 1 hour while keeping the temperature below 75 °C.
  • the reaction mixture was stirred at 65 to 75 °C for 2 hours and then allowed to cool to 20 to 25 °C.
  • the reaction mixture was further cooled to -15 to -5 °C and diluted with ethyl acetate (40.4L) via an addition funnel over 2 hours (very exothermic) while keeping the temperature between -15 to -5 °C.
  • the organic layer was transferred via in-line filter via gas dispersion tube (coarse frit) to a 20 L rotavapor and concentrated under reduced pressure until no more distillate was observed, to obtain 10.0 kg of crude intermediate (12) (racemic) as a light yellow oil, which has 77 wt %of intermediate (12) (racemic) based on 1 H-NMR assay.
  • This oil was dissolved in methanol (6.7 L) and concentrated to furnish 9.13 kg of intermediate (12) (racemic) . (7.73 kg adjusted weight) . This oil was used directly in the next step.
  • Step C) Amination of racemic mixture (12) to provide racemic mixture 2- (aminomethyl) -3, 3, 3-trifluoro-2-hydroxypropanamide (13) .
  • the ethyl acetate layer was then split into 4 equal portions and processed. Each portion was concentrated under reduced pressure to a volume of 7.7 L. This process was repeated for the rest of the three portions. All 4 portions were transferred to the 100 L jacketed reactor and ethyl acetate was added to make up the volume to 46.4 L. The reaction mixture was heated to 55 to 60 °C and heptane (38.7 L) was added over 50 minutes, while maintaining the temperature above 50 °C. The resulting slurry was cooled to 20 to 25 °C, over 2 hours, then held at 20 to 25 °C for 1 hour 30 minutes, and filtered onto an 18 inches Buchner funnel.
  • Step D) chiral resolution of racemic mixture (13) as the D-malic acid salt (14) of (R) -2, 2-dimethyl-5- (trifluoromethyl) oxazolidine-5-carboxamide (20) .
  • (D) - (+) -malic acid (1.56 kg, 11.6 mol, 1.0 equiv) and acetone (30 L) were stirred in a 100 L jacketed reactor.
  • the reaction solution was heated to 33 to 38 °C.
  • 20 %of above intermediate (13) solution in acetone was charged to the 100 L jacketed reactor in one portion followed by a slurry of intermediate (14) (0.52 g) in acetone (20 mL) as seeds.
  • the remaining 80 %of (13) solution in acetone was then charged to the 100 L jacketed reactor over a minimum of 1 hour, while maintaining the reaction temperature between 33 to 38 °C.
  • the reaction mixture was cooled to 28 to 32 °C evenly over a minimum of 2 hour and stirred at 28 to 32 °C for a minimum of 12 hours.
  • the resulting slurry was filtered at 28 to 32 °C, and the filter cake was washed with acetone (16.0 L) (Note: Care was taken to ensure that the filter cake did not dry at the beginning of filtration) .
  • Step E) coupling of Formula VI and malic acid salt (14) to provide (R) -3, 3, 3-trifluoro-2-( ( (5-fluoro-2- (1- (2-fluorobenzyl) -5- (isoxazol-3-yl) -1H-pyrazol-3-yl) pyrimidin-4-yl) amino) methyl) -2-hydroxypropanamide (Formula ID) .
  • the (D) -malic acid salt (14) (0.81 kg, 2.34 moles, 1.25 equiv) and water (0.98 L) were charged to a 30 L jacketed reaction vessel.
  • the reaction mixture was stirred at low speed and the jacket was heated to 65 to 70 °C and held at this temperature for 30 min. Acetone generated during the reaction was removed by applying a gentle vacuum.
  • the reaction mixture was cooled to 20 to 40 °C and Formula VI (0.70 kg, 1.87 moles, 1.0 equiv) , DMSO (9.8 L) and Hunig’s base (0.82 L, 4.71 moles, 2.5 equiv) were charged.
  • the reaction mixture was heated to 88 to 93 °C, over 2 h and held at 88 to 93 °C for 20 h.
  • Hunig’s base (1.96 L, 11.3 moles, 6.0 equiv) was charged followed by water (4.9 L) over 15 min at 50 to 60 °C.
  • the reaction mixture was stirred for 15 min at 50 to 60 °C to form the seed bed.
  • Water (7.0 L) was added via addition funnel at 50 to 60 °C, over 30 min, and the mixture was held at 50 to 60 °C for 30 min.
  • the resulting slurry was filtered at 50 to 60 °C, and the filter cake was washed with a pre-mixed solution of methanol and water (3.5 L/3.5 L) .
  • Step F) hydrolysis of oxazolidine salt malic acid salt (14) to provide the HCl salt (15) of (R) -2- (aminomethyl) -3, 3, 3-trifluoro-2-hydroxypropanamide (15A) .
  • Step vi) coupling of Formula VI and HCl salt (15) to provide (R) -3, 3, 3-trifluoro-2- ( ( (5-fluoro-2- (1- (2-fluorobenzyl) -5- (isoxazol-3-yl) -1H-pyrazol-3-yl) pyrimidin-4-yl) amino) methyl) -2-hydroxypropanamide (Formula ID) .
  • the reaction mixture was cooled to 50 to 55 °C and methanol (4.1 L) was then charged in one portion.
  • Water (2.7 L) was added to the reaction mixture at 50 to 55 °C, over 30 minutes and the reaction mixture was stirred at 50 to 55 °C for 15 minutes to form the seed bed.
  • More water (5.5 L) was added at 50 to 55 °C, over 30 minutes, and the slurry was held at 50 to 55°C for 30 minutes.
  • the slurry was then cooled to 20 to 25 °C, over 1 hour and stirred at 20 to 25 °C for 1 hour.
  • the slurry was filtered, and the filter cake was washed with a pre-mixed solution of methanol and water (10.2 L/10.2 L) .
  • Step vi) coupling of Formula VI and HCl salt (15) to provide (R) -3, 3, 3-trifluoro-2-( ( (5-fluoro-2- (1- (2-fluorobenzyl) -5- (isoxazol-3-yl) -1H-pyrazol-3-yl) pyrimidin-4-yl) amino) methyl) -2-hydroxypropanamide (Formula ID) .
  • the reaction mixture was cooled to 58 to 63 °C and methanol (160 mL) was then charged to the reaction mixture in one portion.
  • Water (60 mL) was added to the reaction mixture at 58 to 63 °C, over 30 minutes, and the reaction mixture was stirred at 58 to 63 °C for 15 minutes to form the seed bed.
  • More water (140 mL) was added at 58 to 63 °C, over 30 minutes, and the slurry was held at 58 to 63°C for 30 minutes.
  • the slurry was then cooled to 30 to 35 °C, over 2 hours and stirred at 30 to 35 °C for 1 hour.
  • Step G) recrystallization of the compound of Formula ID to provide polymorph Form B of the compound of Formula ID (corresponds to steps A” ) , B” ) , C” ) , D” ) and E” ) in the process of preparing the compound of Formula ID or in the 18 th specific embodiment) .
  • the resulting slurry was stirred at 65 to 72 °C, over 1 hour and cooled to 0 to 5 °C, over a minimum of 2 hours and held at 0 to 5 °C for a minimum of 1 hour.
  • the slurry was filtered, and the filter cake was washed with a pre-mixed solution of acetonitrile and water (125 mL/125 mL) .
  • the filter cake was then dried under vacuum at 80 to 95 °C for a minimum of 20 hours to furnish Formula ID, Form B as a white solid (22.7 g, 88 %yield) .
  • Form B of Formula ID was analyzed by XRPD.
  • Form B is characterized by an XRPD pattern as shown in FIGs. 3A, 3B and 3C.
  • Form B is characterized by one or more peaks in the XRPD spectrum at 18.8 to 19.1 °2 ⁇ .
  • Form B is characterized by one or more peaks in the XRPD spectrum selected from: 8.8, 16.4, 17.2, 18.8-19.1, 20.1, and 21.1-21.6 °2 ⁇ .
  • Form B is characterized by one or more peaks in the XRPD spectrum selected from: 8.8, 10.6, 12.6-13.0, 14.6, 16.4, 17.2, 18.8-19.1, 20.1, 21.1-21.6, 24.5, 25.3, 27.0-27.5, 28.9, 29.8 and 30.5°2 ⁇ .
  • Form B is characterized by an XRPD spectrum substantially similar to that shown in FIG. 3C.
  • Form B is characterized by one or more peaks in the XRPD spectrum selected from: 8.9 (76.55%rel int) , 17.4 (57.67%) , 19.1 (100.00%) , and 25.5 (52.26)°2 ⁇ .
  • Form B is characterized by one or more peaks in the XRPD spectrum selected from: 7.0 (44.44%rel int) , 8.9 (76.55%) , 17.4 (57.67%) , 19.1 (100.00%) , 20.3 (49.78%) , 21.8 (36.16%) , and 25.5 (52.26)°2 ⁇ .
  • Form B is characterized by displaying an essentially unchanged XRPD trace when stored for 14 months under the stability conditions of 40 °C and 75 %relative humidity. XRPD traces for Form B before and after storage under those conditions are shown in FIG. 3B.
  • Reagents and conditions (a) NaOMe, MeOH, -15 ⁇ -5°C, 1-2 h; (b) CuI, PdCl2 (PPh3) 2, TMS-Acetylene, Et3N, 20-30°C, 15-20h; (c) KF, MeOH, 20-30°C, 1-2h, 75 ⁇ 84%yield (over three steps) ; (d) n-BuLi, THF, (1') , -78°C, 1-3h; (e) NH (MeO) Me. HCl, 20-30°C, 0.5-1 h, EA, CH3COOH, 75 ⁇ 84%yield (over two steps) ;
  • the temperature should be kept below -10 °C to minimize bismethoxy byproduct.
  • a chase wash of methanol (22.6 kg) followed. Then the mixture was then stirred at -15 ⁇ -5 °C for 1 ⁇ 2 h until the reaction was completed (Note: The temperature should be kept below -10 °C during IPC operation) .
  • the reaction mixture was quenched by the addition of 2M HCl solution (10 kg) over 10 minutes at -15 ⁇ -5 °C (Note: The pH should be adjusted to be 3 ⁇ 4) .
  • Triethylamine (35.2 kg, 347.8 mol, 1.98 equiv) was added into compound (6) /MTBE solution, and then the mixed solution was degassed via bubbling nitrogen for 0.5 ⁇ 1h at 20 ⁇ 30 °C.
  • Pd (PPh 3 ) 2 Cl 2 (0.32 kg, 0.455 mol, 0.0025 equiv)
  • Copper (I) iodide (CuI) (0.17 kg, 0.892 mol, 0.005 equiv) was added to the mixture under N2, and then stirred for 30 min.
  • the organic layer was kept and the aqueous layer was re-extracted with MTBE (80 kg) , settled, separated and the aqueous layer was discarded.
  • the combined organic layer was washed with water (1 X 100 kg) , and then the resulting organic layer was concentrated under vacuum to 3 ⁇ 4 volume (Note: the jacket temperature should be kept below 30 °C) .
  • Methyl cyclohexane (200 kg) was added and then distilled to 3 ⁇ 4 volume below 30 °C.
  • the resulting solution was cooled down to 0 ⁇ 5 °C and stirred for 3 h.
  • the reaction slurry was filtered and the filter cake was washed with pre-cold Methyl cyclohexane (60 kg) .
  • the reaction mixture was transferred from R1 into the vigorously stirred acidic solution in R2 over 10 ⁇ 60 min while maintaining the inner temperature below 10 °C. After transfer, a chase wash of EtOAc (92 kg) was followed to rinse R1 and combined into R2. Then 7%sodium bicarbonate solution (120 kg) was added to the reaction mixture in R2, and the mixture was warmed to 20 ⁇ 30 °C, and then stirred at 20 ⁇ 30 °Cfor 0.5 ⁇ 1 h. (Note: The reaction was monitored by quenching the reaction mixture into acetonitrile/water, and IPC was reported) . The two layers were separated and the aqueous layer was discarded.
  • reaction slurry was stirred at 0 ⁇ 5 °C for another 5 ⁇ 8 h, and then filtered, the filter cake was rinsed with pre-cold methanol.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux procédés permettant de préparer des composés de formule (I). Certains de ces composés sont utiles en tant que stimulateurs de guanylate cyclase soluble (sGC). D'autres sont des intermédiaires utiles pour la préparation desdits stimulateurs. Les procédés selon l'invention sont adaptés à une préparation à grande échelle et permettent d'obtenir des 3-(2-pyrimidinyl)pyrazoles stables de formule (I) avec une haute pureté et des rendements élevés. L'invention présente l'avantage supplémentaire de fournir des conditions de réaction simples pouvant être mises à l'échelle pour une fabrication à grande échelle. La présente invention concerne également de nouveaux intermédiaires utiles dans la préparation de ces composés.
PCT/CN2018/076982 2018-01-10 2018-02-22 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble WO2019161534A1 (fr)

Priority Applications (31)

Application Number Priority Date Filing Date Title
PCT/CN2018/076982 WO2019161534A1 (fr) 2018-02-22 2018-02-22 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble
JOP/2020/0165A JOP20200165A1 (ar) 2018-01-10 2019-01-10 عمليات ووسائط جديدة لتحضير محفزات إنزيم حلقي جوانيلات قابلة للذوبان
AU2019206560A AU2019206560B2 (en) 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
CN201980017700.2A CN111902410B (zh) 2018-01-10 2019-01-10 用于制备可溶性鸟苷酸环化酶刺激剂的方法及中间物
MA051565A MA51565A (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
KR1020207022640A KR20200106920A (ko) 2018-01-10 2019-01-10 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체
CN202410363182.2A CN118184645A (zh) 2018-01-10 2019-01-10 用于制备可溶性鸟苷酸环化酶刺激剂的方法及中间物
PCT/US2019/013060 WO2019140095A1 (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
SG11202006311SA SG11202006311SA (en) 2018-01-10 2019-01-10 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators
EP23187776.2A EP4249469A3 (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
US16/961,109 US11274096B2 (en) 2018-01-10 2019-01-10 Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
TW112138274A TW202402741A (zh) 2018-01-10 2019-01-10 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物
EP19703440.8A EP3737679B1 (fr) 2018-01-10 2019-01-10 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
ES19703440T ES2963447T3 (es) 2018-01-10 2019-01-10 Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble
MX2020007364A MX2020007364A (es) 2018-01-10 2019-01-10 Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.
TW108101044A TWI821237B (zh) 2018-01-10 2019-01-10 用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物
JP2020538535A JP7357621B2 (ja) 2018-01-10 2019-01-10 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
CN202410363184.1A CN118221665A (zh) 2018-01-10 2019-01-10 用于制备可溶性鸟苷酸环化酶刺激剂的方法及中间物
CA3087943A CA3087943A1 (fr) 2018-01-10 2019-01-10 Nouveaux procedes et intermediaires pour la preparation de stimulateurs de la guanylate cyclase soluble
EA202091664A EA202091664A1 (ru) 2018-02-22 2019-01-10 Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
BR112020013985-8A BR112020013985A2 (pt) 2018-01-10 2019-01-10 novos processos e intermediários para a preparação de estimulantes de guanilato ciclase solúvel
IL275748A IL275748A (en) 2018-01-10 2020-06-30 PROCESSES AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF SOLUBLE GIONLIGHT CYCLAS FANS
CL2020001814A CL2020001814A1 (es) 2018-01-10 2020-07-07 Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.
MX2023000045A MX2023000045A (es) 2018-01-10 2020-07-13 Nuevos procesos e intermediarios para la preparacion de estimulantes de guanilato ciclasa soluble.
MX2023000044A MX2023000044A (es) 2018-01-10 2020-07-13 Nuevos procesos e intermediarios para la preparacion de estimulantes de guanilato ciclasa soluble.
US17/497,352 US11708361B2 (en) 2018-01-10 2021-10-08 Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
CL2022000904A CL2022000904A1 (es) 2018-01-10 2022-04-08 Proceso para la preparación de compuestos representados por las fórmulas iv, vii y ia; y un polimorfo del compuesto de fórmula ia (div. sol. 202001814).
CL2022000907A CL2022000907A1 (es) 2018-01-10 2022-04-08 Procesos de preparación de un compuesto de fórmula ib, ic o id; y compuestos intermediarios para fabricar un compuesto de fórmula ib, ic o id (div. sol. 202001814).
US18/140,966 US12030874B2 (en) 2018-02-22 2023-04-28 Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
JP2023162922A JP2023182647A (ja) 2018-01-10 2023-09-26 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
AU2023270260A AU2023270260A1 (en) 2018-01-10 2023-11-22 Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/076982 WO2019161534A1 (fr) 2018-02-22 2018-02-22 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble

Publications (1)

Publication Number Publication Date
WO2019161534A1 true WO2019161534A1 (fr) 2019-08-29

Family

ID=67686627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/076982 WO2019161534A1 (fr) 2018-01-10 2018-02-22 Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble

Country Status (2)

Country Link
EA (1) EA202091664A1 (fr)
WO (1) WO2019161534A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144100A2 (fr) * 2013-03-15 2014-09-18 Takashi Nakai Stimulateurs de sgc
WO2016044447A1 (fr) * 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Dérivés de pyrazole utilisés comme stimulateurs de sgc
WO2017095697A1 (fr) * 2015-11-30 2017-06-08 Ironwood Pharmaceuticals, Inc. Dispersions solides comprenant un stimulateur de guanylate cyclase soluble (sgc)
WO2018009609A1 (fr) * 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Formes solides d'un stimulateur de la gcs
WO2018009602A2 (fr) * 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble
WO2018009597A1 (fr) * 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144100A2 (fr) * 2013-03-15 2014-09-18 Takashi Nakai Stimulateurs de sgc
WO2016044447A1 (fr) * 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Dérivés de pyrazole utilisés comme stimulateurs de sgc
WO2017095697A1 (fr) * 2015-11-30 2017-06-08 Ironwood Pharmaceuticals, Inc. Dispersions solides comprenant un stimulateur de guanylate cyclase soluble (sgc)
WO2018009609A1 (fr) * 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Formes solides d'un stimulateur de la gcs
WO2018009602A2 (fr) * 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble
WO2018009597A1 (fr) * 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble

Also Published As

Publication number Publication date
EA202091664A1 (ru) 2020-12-07

Similar Documents

Publication Publication Date Title
US11708361B2 (en) Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
JP6880127B2 (ja) 多環式カルバモイルピリドン化合物の合成
JP6239139B2 (ja) 新規化合物
CN108699063A (zh) 一种芦可替尼的合成工艺
JP6998896B2 (ja) キラルピロロピリミジン化合物の製造方法
CN111315742A (zh) 制备氨基嘧啶衍生物的改善方法
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
CN115385911A (zh) 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
WO2018009597A1 (fr) Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble
AU2017292811B2 (en) Novel processes for preparation of soluble guanylate cyclase stimulators
US12030874B2 (en) Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
WO2019161534A1 (fr) Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble
CN114057769A (zh) 大环哒嗪类化合物及其用途
RU2630700C2 (ru) СПОСОБЫ ПОЛУЧЕНИЯ 5-[2-[7-(ТРИФТОРМЕТИЛ)-5-[4-(ТРИФТОРМЕТИЛ)ФЕНИЛ]ПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-ИЛ]ЭТИНИЛ]-2-ПИРИДИНАМИНА
EA045335B1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
JP2024524851A (ja) Ｅｒｋ阻害剤を調製するプロセス
CN110759923A (zh) 嘧啶并吡咯并哒嗪衍生物、其中间体、制备方法、药物组合物和用途
WO2016071380A1 (fr) Synthèse d'inhibiteur de pi3k et ses sels
OA19466A (en) Novel processes for preparation of soluble Guanylate Cyclase stimulators.
NZ621156B2 (en) Methods for the preparation of 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]-2-pyridinamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18907171

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 13/01/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 18907171

Country of ref document: EP

Kind code of ref document: A1